New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
May 20, 2015
07:16 EDTMDTLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
05:31 EDTBSXNew study evaluating Boston Scientific Lotus Valve System shows low PVL rates
Subscribe for More Information
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation – JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
12:55 EDTINTCPC related stocks struggle after Morgan Stanley says PC turn won't come until Q3
Subscribe for More Information
11:15 EDTINTCAnalyst says Intel takeover of Altera more likely than not
Citi, in a note to investors today, said that the chances of Altera (ALTR) being acquired by Intel (INTC) were greater than 50%. The note comes after multiple news outlets reported yesterday that the two companies have resumed talks about Intel buying the smaller chip maker. ANALYST REACTION: News reports suggest that the odds of Intel buying Altera seem to have increased, wrote Citi analyst Christopher Danely. A deal is more likely to occur than not, according to the analyst. However, he does not believe that the transaction is a done deal. Moreover, the analyst kept a Neutral rating on Intel shares, saying that he does not anticipate changing his rating even if a takeover is consummated. In its own note on Altera this morning, Pacific Crest said it views the breakdown in Dennard scaling and Dark Silicon as an underappreciated positive for the maker of field-programmable gate arrays. The firm sees fair value for Altera at $55-$60 and still thinks that an acquisition by Intel makes sense strategically. PRICE ACTION: In late morning trading, Altera added 0.5% to $47.16, while Intel fell 1% to $33.06.
09:17 EDTINTCAltera has 'underappreciated' positive catalyst, says Pacific Crest
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
08:34 EDTINTCApple introduces 15-inch MacBook Pro with Force Touch trackpad
Subscribe for More Information
08:33 EDTINTCMorgan Stanley cautious in near-term on PC names
Morgan Stanley is more cautious on PC names near-term, given PC and HDD inventory builds quarter-to-date and weaker April ODM sales. The firm's analyst team continues to believe Q1 was a bottom in year-over-year growth, but now expects normal Q2 seasonal growth instead of above normal and thinks any recovery will likely be delayed until Q3. Morgan Stanley is cautiously optimistic on Western Digital (WDC) due to its diverse revenue drivers, sees value creation catalysts for Hewlett-Packard (HPQ) and believes Microsoft (MSFT) shares reflect the challenging PC market and Win 10. The firm is more cautious on semis such as NVIDIA (NVDA) given higher valuations, share loss at Advanced Micro (AMD), potential 2H margin pressure at Intel (INTC), and Morgan is cautious on PC DRAM stocks near-term due to weaker pricing.
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
06:10 EDTINTCCiti sees over 50% chance of Intel buying Altera
Subscribe for More Information
May 18, 2015
12:51 EDTINTCOn The Fly: Top stock stories at midday
Subscribe for More Information
10:40 EDTINTCIntel, Altera held principal to principal talks late last week, Faber says
Subscribe for More Information
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information
09:11 EDTINTCIntel, Altera held 'principal to principal' talks last week, CNBC reports
Subscribe for More Information
07:06 EDTINTCAltera back in talks with Intel about potential takeover, NY Post says
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use